The Dopamine Hypothesis of Schizophrenia: An Historical and ...

More documents

Recommendations

Info

Kendler and Schaffner / Dopamine Hypothesis of Schizophrenia ■ 61 Dorling, J. 1979. Bayesian personalism, the methodology of scientific-research programs, and Duhem’s problem. Studies in History and Philosophy of Science 10, no. 3:177–87. Falck, B., N. A. Hillarp, G. Thieme, and A. Torp. 1982. Fluorescence of catechol amines and related compounds condensed with formaldehyde. Brain Research Bulletin 9, no. 1–6:xi–xv. Fan, J. B., C. S. Zhang, N. F. Gu, X. W. Li, et al. 2005. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biological Psychiatry 57, no. 2:139–44. Farley, I. J., K. S. Price, and O. Hornykiewicz. 1977. Dopamine in the limbic regions of the human brain: Normal and abnormal. Advances in Biochemical Psychopharmacology 16:57–64. Faurbye, A. 1968. The role of amines in the etiology of schizophrenia. Comprehensive Psychiatry 9, no. 2:155–77. Fuxe, K., T. Hokfelt, O. Nilsson, and S. Reinius. 1966. A fluorescence and electron microscopic study on central monoamine nerve cells. Anatomical Record 155, no. 1:33–40. Gamma, F., S. V. Faraone, S. J. Glatt, Y. C. Yeh, et al. 2005. Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene. Schizophrenia Research 73, no. 1:55–8. Garcia, A., A. Galinowski, P. Guicheney, E. Mignot, et al. 1989. Free and conjugated plasma homovanillic acid in schizophrenic patients. Biological Psychiatry 26, no. 1:87–96. Gazzaniga, M. S. 2004. The cognitive neurosciences III, 3rd ed. Cambrdige, MA: The MIT Press. Glatt, S. J., S. V. Faraone, and M. T. Tsuang. 2004. DRD2-141C insertion/deletion polymorphism is not associated with schizophrenia: Results of a metaanalysis. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 128B, no. 1:21–3. ——–. 2006. The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: Evidence from fixed- and randomeffects meta-analyses. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 141, no. 2:149–54. Griffiths, J. J., J. Oates, and J. Cavanaugh. 1968. Paranoid episodes induced by drugs. Journal of the American Medical Association 205:39–46. Gunderson, J. G., M. C. Zanarini, C. L. Kisiel. 1995. Borderline personality disorder. In The DSM-IV personality disorders, ed. W. J. Livesley, 141–57. New York: The Guilford Press. Harrison, P. J., and D. R. Weinberger. 2005. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Molecular Psychiatry 10, no. 1:40–68. Hietala, J., and E. Syvalahti. 1996. Dopamine in schizophrenia. Annals of Medicine 28, no. 6:557–61. Hökfelt, T., A. Ljungdahl, K. Fuxe, and O. Johansson. 1974. Dopamine nerve terminals in the rat limbic cortex: Aspects of the dopamine hypothesis of schizophrenia. Science 184, no. 133:177–9. Hoogendoorn, M., S. Bakker, H. Schnack, J. Selten, et al. 2005. No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 134B:6–9. Howson, C., and P. Urbach. 2005. Scientific reasoning: The Bayesian approach, 3rd ed. Chicago: Open Court Publishing Company. Jonsson, E. G., R. Kaiser, J. Brockmoller, V. L. Nimgaonkar, et al. 2004. Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatric Genetics 14, no. 1:9–12. Jonsson, E. G., G. C. Sedvall, M. M. Nothen, and S. Cichon. 2003. Dopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analyses. Schizophrenia Research 61, no. 1:111–9. Kandel, E. R., J. H. Schwartz, and T. M. Jessell. 2000. Principles of neural science, 4th ed. New York: McGraw-Hill Medical. Katz, B. 1994. Planning and following the unexpected in scientific-research. Creativity Research Journal 7, no. 3–4:225–38. Kebabian, J. W., and D. B. Calne. 1979. Multiple receptors for dopamine. Nature 277, no. 5692:93–6. Kendler, K. S. 2005. Toward a philosophical structure for psychiatry. American Journal of Psychiatry 163, no. 3:433–40. Kendler, K. S., R. C. Mohs, and K. L. Davis. 1983. The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatry Research 8, no. 3:215–23. Kendler, K. S., and J. Parnas. 2008. Philosophical issues in psychiatry: Explanation, phenomenology and nosology. Baltimore, MD: The Johns Hopkins University Press. Kestler, L. P., E. Walker, and E. M. Vega. 2001. Dopamine receptors in the brains of schizophrenia patients: A meta-analysis of the findings. Behavioural Pharmacology 12, no. 5:355–71. Kety, S. 1959. Biochemical theories of schizophrenia. Science 129:1528–32. ——–. 1966. Catecholamines in neuropsychiatric states. Pharmacology Review 18, no. 1:787–98.
62 ■ PPP / Vol. 18, No. 1 / March 2011 Kitcher, P. 1993. The advancement of science: Science without legend, objectivity without illusions. New York: Oxford University Press. Kojima, H., O. Ohmori, T. Shinkai, T. Terao, et al. 1999. Dopamine D1 receptor gene polymorphism and schizophrenia in Japan. American Journal of Medical Genetics 88, no. 2:116–9. Koob, G. F., and M. Le Moal. 2006. Psychostimulants. In Neurobiology of addiction, ed. G. F. Koob, and M. Le Moal, 69–120. London: Academic Press, Elsevier, Inc. Kopin, I. J. 1993. Parkinson’s disease: Past, present, and future. Neuropsychopharmacology 9, no. 1:1–12. Kuhn, T. S. 1996. The structure of scientific revolutions, 3rd ed. Chicago: University of Chicago Press. Lacasse, J. R., and J. Leo. 2005. Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med 2, no. 12:e392. Lakatos, I. 1970. Falsification and the methodology of scientific research programmes. In Criticism and the growth of knowledge, ed. I. Lakatos, and A. Musgrave, 91–197. London: Cambridge University Press. Laudan, L. 1977. Progress and its problems. Berkeley: University of California Press. Lieberman, J. A., J. M. Kane, and J. Alvir. 1987. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415–33. Maas, J. W., S. A. Contreras, A. L. Miller, N. Berman, et al. 1993. Studies of catecholamine metabolism in schizophrenia/psychosis—I. Neuropsychopharmacology 8, no. 2:97–109. Magee, B. 1982. Popper. London: Fontana Paperbacks. Marx, C. E., and J. A. Lieberman. 1998. Psychoneuroendocrinology of schizophrenia. Psychiatric Clinics of North America 21, no. 2:413–34. Matthysse, S. 1973. Antipsychotic drug actions—Clue to neuropathology of schizophrenia. Federation Proceedings 32, no. 2:200–5. Matthysse, S., and J. Lipinski. 1975. Biochemical aspects of schizophrenia. Annual Review of Medicine 26:551–65. Meltzer, H. Y., and S. M. Stahl. 1976. The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bulletin 2, no. 1:19–76. Montagu, K. A. 1957. Catechol compounds in rat tissues and in brains of different animals. Nature 180, no. 4579:244–5. Munafo, M. R., L. Bowes, T. G. Clark, and J. Flint. 2005. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Molecular Psychiatry 10, no. 8:765–70. Owen, M. J., N. M. Williams, and M. C. O’Donovan. 2004. The molecular genetics of schizophrenia: New findings promise new insights. Molecular Psychiatry 9, no. 1:14–27. Pae, C. U., J. J. Kim, A. Serretti, C. U. Lee, et al. 2003. VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. Neuropsychobiology 47, no. 3:131–6. Platt, J. R. 1964. Strong inference. Science 146, no. 3642: 347–53. Popper, K. R. 1959. The logic of scientific discovery. New York: Basic Books. ——–. 1962. Conjectures and refutations. New York: Basic Books. Predescu, V., D. Florescu, and C. Radulesc. 1968. Pink spot as a diagnostic test in schizophrenia. Nature 217, no. 5134:1150. Schaffner, K. F. 1992. Theory change in immunology. 2. The clonal selection theory. Theoretical Medicine 13, no. 2:175–216. ——–. 1993. Discovery and explanation in biology and medicine. Chicago: The University of Chicago Press. ——–. 1994. Psychiatry and molecular biology: Reductionistic approaches to schizophrenia in philosophical perspectives on psychiatric diagnostic classification. Baltimore, MD: The Johns Hopkins University Press. ——–. 2002. Clinical and etiological psychiatric diagnoses: Do causes count? In Descriptions and prescriptions: Values, mental disorders, and the DSMs, ed. J. Z. Sadler, 271–90. Baltimore, MD: The Johns Hopkins University Press. Seeman, P., T. Lee, M. Chauwong, and K. Wong. 1976. Antipsychotic drug doses and neuroleptic-dopamine receptors. Nature 261, no. 5562:717–9. Shapere, D., and D. R. Dordrecht. 1984. Reason and the search for knowledge: Investigations in the philosophy of science (Boston studies in the philosophy of science). Boston: D. Reidel Publishing Company. Shifman, S., M. Bronstein, M. Sternfeld, A. Pisante- Shalom, et al. 2002. A highly significant association between a COMT haplotype and schizophrenia. American Journal of Human Genetics 71, no. 6:1296–302. Shorter, E. 1997. A history of psychiatry: From the era of the asylum to the age of Prozac. New York: John Wiley & Sons, Inc. Skare, S. S., M. W. Dysken, and C. J. Billington. 1994. A review of GHRH stimulation test in psychiatry. Biological Psychiatry 36, no. 4:249–65. Snyder, S. H. 1976. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. American Journal of Psychiatry 133, no. 2:197–202. Snyder, S. H., G. K. Aghajanian, and S. Matthysse. 1972. Prospects for research on schizophrenia. V. Pharmacological observations, drug-induced psy-
Page 1 and 2: The Dopamine Hypothesis of Schizoph
Page 3 and 4: 42 ■ PPP / Vol. 18, No. 1 / March
Page 21: 60 ■ PPP / Vol. 18, No. 1 / March

The Dopamine Hypothesis of Schizophrenia: An Historical and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?